Study on the Experimental Methodology of Plasma Clot Retraction
10.19746/j.cnki.issn1009-2137.2024.04.045
- VernacularTitle:血浆凝块收缩功能实验方法学研究
- Author:
Yang-Gan LUO
1
;
Zi-Han LU
;
Han-Jing LIAO
;
Dou-Dou HAO
;
Man-Jing HUANG
;
Zhi-Xiang ZHU
Author Information
1. 北京中医药大学中药学院,北京 100029
- Keywords:
plasma clot retraction;
thrombin;
Ca2+;
platelets;
signaling pathway inhibitors
- From:
Journal of Experimental Hematology
2024;32(4):1271-1277
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the key factors affecting plasma clot retraction and optimize the experimental method of plasma clot retraction,in order to study the regulation of platelet function and evaluate the modulatory effects of drugs on plasma clot retraction.Methods:The effects of different concentrations of thrombin,Ca2+and platelets on plasma clot retraction were studied,and the detection system of plasma clot retraction was optimized.The availability of the detection system was then validated by analyzing the regulatory effects of multiple signaling pathway inhibitors on plasma clot retraction.Results:Through the optimization study of multiple factors,platelet rich plasma(PRP)containing 0.5 mmol/L Ca2+and 40 × 109/L platelets was treated with 0.2 U/ml thrombin to perform plasma clot retraction analysis.After treatment with thrombin for 15 min,plasma clot retracted significantly.After treatment with thrombin for 30 min,the percentage of plasma clot retraction was more than 50％.The regulatory effects of multiple signaling pathway inhibitors on plasma clot retraction were studied in this detection system.PKC inhibitor Go 6983 exhibited a significant inhibitory effect on plasma clot retraction,while PI3K inhibitor Ly294002 and p38 MAPK inhibitor SB203580 slightly suppressed plasma clot retraction.Conclusion:PRP containing 0.5 mmol/L Ca2+and 40 × 109/L platelets can be induced with 0.2 U/ml thrombin to conduct plasma clot retraction analysis,which can be used to study the regulation of platelet function and evaluate the modulatory effects of drugs on plasma clot retraction.
